Address: Pimonenko Ulitsa 13, build. 5A, off. 41, 04050 Kiev,Ukraine
Tel: +38 (044) 490 6826
Astellas is one of the top 20 pharmaceutical companies in the world, employing 14,000 people globally. As a young and forward-thinking company, Astellas is dedicated to improving the lives of people around the world through the introduction of innovative and reliable pharmaceutical products.
Now five years on from the merger of Yamanouchi and Fujisawa, Astellas continues to remain committed to developing first-in-class and best-in-class products in key therapeutic areas by combining outstanding R&D with marketing capabilities and continuing growth in the world pharmaceutical market.
Astellas Pharma Europe Ltd. is focused on five key therapeutic areas: Transplantation, Urology, Dermatology, Anti-infectives, and Pain Management. In addition, Astellas remains committed to improving the lives of patients with a number of other diseases, including Diabetes and Cardiovascular, CNS, Respiratory, and Gastrointestinal. As an organisation, Astellas is focused on and committed to its R&D programmes and is driven by its philosophy of enriching the lives of people around the world.
Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi…
Igor Bondarenko of Ukraine’s Dnipro State Medical University, Evgeny Levenko from clinical trials company, ARENSIA, and Olena Popova from IQVIA offer their perspectives on maintaining quality and ensuring participant protection…
The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Here, Chieko…
The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Anina Adelfio…
Russia’s invasion of Ukraine has been roundly condemned by the pharmaceutical industry and almost all Big Pharmas have pledged humanitarian support to Ukraine. However, not all companies have followed the…
Ukraine’s bold decision to outsource public procurement of medicines to international agencies to combat rampant corruption has been well received by the pharma MNCs operational in the country, but faces…
Vladimir Sayenko, founding partner, and Anzhela Makhinova, counsel, of the leading Ukrainian law firm Sayenko Kharenko, give an overview on the Ukrainian pharmaceutical industry in 2017 and explain the expansion…
Tetiana Korotchenko, Country Representative of Crown Agents, one of the three international organizations contracted by the Ukrainian government to temporarily handle healthcare procurement and put an end to the plague…
Dmytro Popov, the owner, founder and CEO Elfa Group, Ukraine’s leading cosmetics manufacturer, provides his insight into Elfa’s 20-year presence in the Ukrainian market, the company’s international growth strategies and…
Dr. Maxim Sokolov, chief external specialist of the Ministry of Health of Ukraine in cardiology, principal scientist of the Department of Interventional Cardiology of the National Academy of Medical Sciences…
Dr. Paul Melekhov, vice president Eastern Europe at Pharmascience, Canada’s third largest generic company, provides insights into the unique history of Pharmascience in Ukraine and the pioneering market approach that…
Julia Sidorova, country manager of Alvogen, a new international player to the Ukrainian market, provides insights into the targeted strategy that Alvogen employs throughout the world and how this is…
Victoria Filatova, president and chairperson of the Association of Perfumery and Cosmetics of Ukraine (APCU), discusses her strategic priorities, the association’s main achievements in its six years of existence, and…
See our Cookie Privacy Policy Here
